Researchers have developed a new radiotracer, FDT, which enables accurate detection of live TB bacteria in the body. This approach is more specific than existing methods and could lead to improved diagnosis and treatment outcomes for TB patients.
A new analysis method reveals that the original SARS-CoV-2 viral strain used a sugar binding feature to infect human cells, which was later lost in variants. This discovery raises questions about the origins of the virus and its transmission to humans.
Researchers at the Rosalind Franklin Institute have developed nanobodies from llama antibodies that can effectively target SARS-CoV-2 virus. These nanobodies were able to significantly reduce signs of COVID-19 disease in infected animal models and show promise as a new treatment option.
The new Quantum C100 detector enables radical simplification of microscope design, making cryoEM widely available and accessible. This will benefit society by increasing the democratization of cryoEM technology.
Researchers at The Rosalind Franklin Institute have engineered llama antibodies that can bind to the SARS-CoV-2 virus, blocking its entry into human cells. These nanobodies show promise as a potential treatment for patients with severe COVID-19.
Nanobodies have been isolated and made available for researchers to study the 'spike' protein of SARS-CoV-2 virus. These proteins can stabilise the 'spike', enabling better imaging at an atomic scale, which could lead to new diagnostics and treatments.
The Rosalind Franklin Institute has committed to developing a new detector for low-energy cryoEM, enabling atomic-scale images of biological samples. The goal is to make cryoEM more accessible and affordable, allowing for faster scientific progress in medical research and drug development.